Skip to main content

Table 2 Study endpoints

From: The INCA trial (Impact of NOD2 genotype-guided antibiotic prevention on survival in patients with liver Cirrhosis and Ascites): study protocol for a randomized controlled trial

Primary endpoint

Secondary endpoints

Overall survival after 12 months

Spontaneous bacterial peritonitis within 12 months

 

Other clinically significant infections (for example, urinary tract infections, pneumonia, sepsis, bacteremia) requiring antimicrobial treatment within 12 months

 

Duration of unscheduled cirrhosis-associated hospitalization within 12 months